Novartis Investigative Site

New London, Connecticut 06320

0 studies enrolling now · 3 studies all time

What they study most

Neovascular Age-related Macular Degeneration, Relapsing Forms of Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis

Studies at this site

• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed